Keyword Technology Search Result
MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections. According to GlobalData, Phase III drugs for Influenza A Virus, H3N2 Subty
Website link :https://adquash.com/news_q.php?str=MRNA-1083_by_Moderna_for_Influenza_A_Virus,_H3N2_Subtype_Infections:_Likelihood_of_Approval_1189
Millions of Satellites Could Have a Profound Effect on the Earth’s Ionosphere
Hardly a day goes by where a story hits the headlines about our abuse of the Earth’s precious environment be that the atmosphere or the oceans, forests or desert. When it comes to the atmosphere we
Website link :https://adquash.com/news_q.php?str=Millions-of-Satellites-Could-Have-a-Profound-Effect-on-the-Earths-Ionosphere
A New Weapon Against Climate Change – Scientists Develop “Cooling Glass” That Blasts Building Heat Into Space
An innovative “cooling glass” developed by University of Maryland researchers offers a groundbreaking, electricity-free solution for reducing indoor heat and carbon emissions, marking a significan
Website link :https://adquash.com/news_q.php?str=A-New-Weapon-Against-Climate-Change--Scientists-Develop-Cooling-Glass-That-Blasts-Building-Heat-Into-Space
Tiragolumab by Genentech USA for Gastric Cancer: Likelihood of Approval
Tiragolumab is under clinical development by and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) in
Website link :https://adquash.com/news_q.php?str=Tiragolumab_by_Genentech_USA_for_Gastric_Cancer:_Likelihood_of_Approval_692
Consett Reimagined using Artificial Intelligence
GPT-4 and DALL·E Transforming Reality in Consett, County Durham Discover Consett’s AI Revolution : Digitally reimagining Consett Local company Firefly New Media UK is conducting an experiment invol
Website link :https://adquash.com/news_q.php?str=Consett_Reimagined_using_Artificial_Intelligence_1205
Bevacizumab biosimilar by Gedeon Richter for Metastatic Breast Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 82% phase tra
Website link :https://adquash.com/news_q.php?str=Bevacizumab_biosimilar_by_Gedeon_Richter_for_Metastatic_Breast_Cancer:_Likelihood_of_Approval_693
Disitamab vedotin by Seagen for Urethral Cancer: Likelihood of Approval
Disitamab vedotin is under clinical development by and currently in Phase II for Urethral Cancer. According to GlobalData, Phase II drugs for Urethral Cancer does not have sufficient historical data t
Website link :https://adquash.com/news_q.php?str=Disitamab_vedotin_by_Seagen_for_Urethral_Cancer:_Likelihood_of_Approval_694
Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to GlobalData, Phase II drugs for Anaplasti
Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Anaplastic_Large_Cell_Lymphoma_(ALCL):_Likelihood_of_Approval_698
Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Natural Killer Cell Lymphomas: Likelihood of Approval
Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData, Phase II drugs for Natural Killer Ce
Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Natural_Killer_Cell_Lymphomas:_Likelihood_of_Approval_700
Epcoritamab by Genmab for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Epcoritamab is under clinical development by and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leu
Website link :https://adquash.com/news_q.php?str=Epcoritamab_by_Genmab_for_Refractory_Chronic_Lymphocytic_Leukemia_(CLL):_Likelihood_of_Approval_701
NKX-019 by Nkarta for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
NKX-019 is under clinical development by and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinem
Website link :https://adquash.com/news_q.php?str=NKX-019_by_Nkarta_for_Waldenstrom_Macroglobulinemia_(Lymphoplasmacytic_Lymphoma):_Likelihood_of_Approval_708
Bittera by Aardvark Therapeutics for Prader-Willi Syndrome (PWS): Likelihood of Approval
Bittera is under clinical development by Aardvark Therapeutics and currently in Phase II for Prader-Willi Syndrome (PWS). According to GlobalData, Phase II drugs for Prader-Willi Syndrome (PWS) have a
Website link :https://adquash.com/news_q.php?str=Bittera_by_Aardvark_Therapeutics_for_Prader-Willi_Syndrome_(PWS):_Likelihood_of_Approval_711
